Seer, Inc.

Today, and thank you for standing by, welcome to SEER First Quarter 2021 Earnings Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question and answer session. To ask a question during that time, you will need to press star 1 on your telephone. If you require any further assistance, please press star 0. I would now like to hand the conference over to your speaker, Carrie Mandeville, with Investor Relations. Thank you.

Earlier today, SEER released financial results for the quarter ending March 31st, 2021. If you have not received this news release, or if you'd like to be added to the company's distribution list, please send an email to investor at seer.bio. Joining me today from SEER is Omid Farraqzad, Chairman, Chief Executive Officer and Founder, Omid Ostudan, President and Chief Operating Officer, and David Horn, Chief Financial Officer. Before we begin, I'd like to remind you that management will make statements during this call that are forward-looking statements within the meaning of federal securities laws. These statements involve material risks and uncertainties that could cause actual results or events to materially differ from those anticipated. Additional information regarding these risks and uncertainties appears in the section entitled forward-looking statements in the press release here issued today. For a more complete list and description, please see the risk factors section in the company's quarterly report on form 10Q for the quarter ending March 31st, 2021. And then this other filing with the Securities and Exchange Commission. Except as required by law, SEER disclaims any intention or obligation to update or revise any financial projections or forward-looking statements, whether because of new information, future events, or otherwise. This conference call contains time-sensitive information and is accurate only as of the live broadcast May 10th, 2021. With that, I'd like to turn the call over to Omid.

Thanks, Kerry. We're making strong progress across all areas of our business and business strategy, adding to our talented team, expanding our commercial reach, and broadening access to the Protograph product suite. We're enabling more researchers to undertake proteomic studies that will undoubtedly drive novel biological insights, create and expand new markets, and ultimately improve human health. To further drive this momentum, we continue to be focused on four areas. First, setting the pace for innovation in the proteomics space. Second, leveraging the unique capabilities of our differentiated solutions. Third, coupling exceptional customer experience with transformative products. And fourth, forming strategic relationships with key customers and partners. And of course, most importantly, the foundation for all of this is predicated on continuing to grow an incredibly talented team. Since we last updated you at the end of March, we have continued to build on our strong start to the year. Demand for the Proteograph product suite is exceptionally strong, and our value proposition is resonating with prospective customers across the globe. We expect our message to amplify even more as we ramp up on marketing activities and scale our commercial organization. Even with this strong market demand, we remain committed to a measured commercial approach, and you will hear more about this from Omid. With all full collaboration customers up and running, we have commenced limited release by signing multiple customers since our last earning call. We expect to have high single digit number of limited release customers before we commence broad release, and we're on track to deliver against this objective. These initial limited release customers also include prognomic, which we spun out last fall and retained 19% ownership. Prognomic will be using the Proteograph product suite for liquid biopsies across a range of applications, including early disease detection and proteogenomics. We believe Prognomic can play a key role in demonstrating the impact of unbiased and deep plasma proteomics in these applications. accelerating the realization of a market opportunity that we already believe to be very large. Our goal is to create an ecosystem around our technology and its broad use in proteomics and proteogenomics. This is a critical part of our strategy. Our partnership with the leading mass spec companies, our three-phase commercial approach, and our spin-out of Prognomic are all evidence of this strategy in action. We believe this will set us up long-term success and broad-scale adoption of our proteograph product suite. It is clear that customers are eager to perform studies using unbiased deep plasma proteomics at scale, and early customer data is providing strong evidence of the depth and breadth of proteomic access that can be generated easily from our platform. Both OHSU Knight Cancer Institute and the Broad have completed their initial evaluation studies, which demonstrated encouraging results. They're progressing toward the next set of larger-scale studies. In particular, OHSU's initial pilot has spurred plans for several large-scale projects including one looking at proteomic signatures of prostate cancer. Again, Omid will give you more color on this shortly. Discovery Life Sciences is already preparing to run samples for large-scale proteogenomic projects in a complex disease, which is one of the use cases uniquely enabled by our technology. The Salk Institute, our fourth collaboration site, has received their instrument and we have already completed installation. They will be up and running with samples in the coming weeks. We expect you will begin to hear more from each of these collaboration customers as their studies progress and they're in a position to share their experiences and results through presentations or publications. We continued to strengthen our leadership team, welcoming Kenny Ross as our new vice president for operations and quality. Kenny brings with him over 30 years of experience in operations and quality and life sciences, having previously held senior leadership roles at Applied Biosystems, Life Technologies, and most recently, Illumina, where he served as Vice President, Manufacturing Strategy. And finally, we doubled a Redwood City footprint to support our growing organization, expanding our lease to a total of 50,000 square feet of state-of-the-art office and research space. There continues to be a growing enthusiasm and energy in the proteomic space. And what we're doing at SEER is truly differentiated. We are developing innovative solutions to empower the scientific community to arrive at exceptional proteomics outcomes. We have developed a proteograph product suite, a first-of-its-kind solution, leveraging our proprietary nanoparticle technology to enable unbiased, deep proteomics at scale, eliminating the needs for scientists to make tradeoffs between depth of coverage and scale when designing their unbiased proteomic studies. Our solution is the only available state-of-the-art technology to deliver peptide and amino acid level resolution, which is necessary to match nucleotide level genomics information and broadly enable proteogenomics. The proteograph has been designed to fit in front of nearly any detector, making it easy for those who are adding proteomics to their studies to easily integrate it into their workflow. The proteograph allows nearly any lab to undertake these studies in a way that is not possible today without tradeoffs. And through these capabilities, we expect our solution will enable population-scale studies that will enrich biological datasets and enhance the number of biomarkers and drug targets, and we believe the overall impact on human health will be enormous. We are very much at the onset of this journey to transform accessibility of the proteome by finally eliminating the longstanding technology barrier that has prevented researchers from tapping into this rich, critical source of biological information. And while much work remains, we're excited and inspired by the opportunity that lays in front of us. With that, I will now turn the call over to Amit for more detail on our commercial progress.